Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| Weiss Ratings | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.41 | |||
| Price History | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.77% | |||
| 30-Day Total Return | 46.75% | |||
| 60-Day Total Return | 50.30% | |||
| 90-Day Total Return | 39.33% | |||
| Year to Date Total Return | 55.00% | |||
| 1-Year Total Return | -16.22% | |||
| 2-Year Total Return | 19.23% | |||
| 3-Year Total Return | -54.91% | |||
| 5-Year Total Return | -77.62% | |||
| 52-Week High % Change | -39.19% | |||
| 52-Week Low % Change | 129.81% | |||
| Price | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.93 | |||
| 52-Week Low Price | $1.04 | |||
| 52-Week Low Price (Date) | Nov 12, 2024 | |||
| 52-Week High Price (Date) | Jun 12, 2024 | |||
| Valuation | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 364.07M | |||
| Enterprise Value | 482.55M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.09 | |||
| Earnings Per Share Growth | -89.72% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.54 | |||
| Price/Book (Q) | -10.80 | |||
| Enterprise Value/Revenue (TTM) | 3.34 | |||
| Price | $2.48 | |||
| Enterprise Value/EBITDA (TTM) | -53.40 | |||
| Enterprise Value/EBIT | -41.86 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 153.15M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (858) 251-4400 | |||
| Address | 100 Regency Forest Drive Cary, NC 27518 | |||
| Website | www.herontx.com | |||
| Country | United States | |||
| Year Founded | 1983 | |||
| Profitability | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -7.98% | |||
| Profit Margin | -9.41% | |||
| Management Effectiveness | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -3.16% | |||
| Return on Equity | -- | |||
| Income Statement | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 144.29M | |||
| Total Revenue (TTM) | 144.29M | |||
| Revenue Per Share | $0.94 | |||
| Gross Profit (TTM) | 88.95M | |||
| EBITDA (TTM) | -9.04M | |||
| EBIT (TTM) | -11.53M | |||
| Net Income (TTM) | -13.58M | |||
| Net Income Avl. to Common (TTM) | -13.58M | |||
| Total Revenue Growth (Q YOY) | 19.13% | |||
| Earnings Growth (Q YOY) | 134.16% | |||
| EPS Diluted (TTM) | -0.09 | |||
| EPS Diluted Growth (Q YOY) | 134.14% | |||
| Balance Sheet | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 59.28M | |||
| Cash Per Share (Q) | $0.39 | |||
| Total Current Assets (Q) | 209.01M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -33.65M | |||
| Current Ratio (Q) | 2.285 | |||
| Book Value Per Share (Q) | -$0.22 | |||
| Total Assets (Q) | 233.15M | |||
| Total Current Liabilities (Q) | 91.46M | |||
| Total Debt (Q) | 177.76M | |||
| Total Liabilities (Q) | 266.80M | |||
| Total Common Equity (Q) | -33.65M | |||
| Cash Flow | HRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 18.71M | |||
| Cash from Financing (TTM) | 940.00K | |||
| Net Change in Cash (TTM) | -2.88M | |||
| Levered Free Cash Flow (TTM) | -25.95M | |||
| Cash from Operations (TTM) | -22.53M | |||
